Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

Hepatology

Volumn 27, Issue 6, 1998, Pages 1711-1716

  Chayama, Kazuaki ^a   Suzuki, Yoshiyuki ^a   Kobayashi, Masahiro ^a   Kobayashi, Mizuho ^a   Tsubota, Akihito ^a   Hashimoto, Michie ^a   Miyano, Yukiko ^a   Koike, Hiromi ^a   Kobayashi, Mariko ^a   Koida, Isao ^a   Arase, Yasuji ^a   Saitoh, Satoshi ^a   Murashima, Naoya ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DNA POLYMERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LONG TERM CARE; MALE; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS MUTANT; VIRUS REPLICATION;

ADULT; AMINO ACID SEQUENCE; BASE SEQUENCE; DRUG RESISTANCE, MICROBIAL; FEMALE; GENES, VIRAL; GENOME, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS;

EID: 17344373482     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510270634     Document Type: Article

References (33)

1. Chang CM, Skalski V, Zhou JH, Cheng YC. Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 1992;31:22414-22420.
2. Chang CN, Doong SL, Zhou JH, Beach JW, Jeong LS, Chu CK, Tsai CH, et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem 1992;20:13938-13942.
3. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;19:8495-8499.
4. Charvet AS, Turin F, Faury P, Hantz O, Camplo M, Mourier N, Berthillon P, et al. Synthesis and antiviral activity of new carbonylphosphonate 2′,3′-dideoxy-3′-thiacytidine conjugates. Antiviral Res 1994;2:161-168.
5. Mansour TS, Jin H, Wang W, Hooker EU, Ashman C, Cammack N, Salomon H, et al. Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2′-deoxy-3′-oxa-4′-thiocytidine and their 5-fluoro analogues in vitro. J Med Chem 1995;1:1-4.
6. Severni A, Liu X, Wilson JS, Tyrrell DL. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-L-2′,3′-dideoxy -3′-thiacytidine. Antimicrob Agents Chemother 1995;39:1430-1435.
7. Korba BE. In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res 1995;29:49-51.
8. Fischer KP, Tyrrell DL. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-β-L-2′,3′-dideoxy-3′-thiacytidine] in vitro. Antimicrob Agents Chemother 1996;40:957-1960
9. Xie H, Voronkov M, Liotta DC, Korba BA, Schinazi RF, Richman DD, Hostetler KY. Phosphatidy1-2′,3′-dideoxy-3′-thiacytidine:synthesis and activity in hepatitis B- and HIV-1-infected cells. Antiviral Res 1995;28:113-120.
10. Pajagopalan P, Boudinot F, Chu CK, Tennant BC, Baldwin BH, Schinazi RF. Pharmacokinetics of (-)-2′-3′-dideoxy-3′-thiacytidine in woodchucks. Antimicrob Agents Chemother 1996;40:642-645.
11. Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, Wong BC, Dent J, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. HEPATOLOGY 1997;1:241-244.
12. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, Tubiana R, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996;125:705-712.
13. Ben-Ari Z, Shmueli D, Mor E, Shapira Z, Tur-Kaspa R. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 1997;3:393-396.
14. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, McMaster P, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;9036:1212-1215.
15. Benhamou Y, Dohin E, Lunel-Fabiani F, Poynard T, Huraux JM, Katlama C, Opolon P, et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients [Letter]. Lancet 1995;8946:396-397.
16. Schnittman SM, Pierce PE Potential role of lamivudine (3TC) in the clearance of immunodeficiency virus type. Clin Infect Dis 1996;3:638-639.
17. Schalm SW, de Man RA, Heijtink RA, Niesters HG. New nucleoside analogues for chronic hepatitis B. J Hepatol 1995;l:52-56.
18. Hoofnagle JH, Lau D. New therapies for chronic hepatitis B. J Viral Hepat 1997;4(Suppl 1):41-50.
19. Grellier L, Dusheiko GM. Hepatitis B virus and liver transplantation: concepts in antiviral prophylaxis. J Viral Hepat 1997;(Suppl 1):111-116.
20. Honkoop P, de Man RA, Zondervan PE, Schalm SW. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 1997;2:103-106.
21. Bain VG, Kneteman NM, Ma MM, Gutfreund K, Shapiro JA, Fischer K, Tipples G, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996;10:1456-1462.
22. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;25:1657-1661.
23. Balzarini J, Wedgwood O, Kruining J, Pelemans H, Heijtink R, De Clercq E, McGuigan C. Anti-HIV and anti-HBV activity and resistance profile of 2′,3′-dideoxy-3′-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. Biochem Biophys Res Commun 1996;2:363-369.
24. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation [Comments]. Lancet 1997;9044:20-22.
25. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. HEPATOLOGY 1996;3:711-713.
26. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. HEPATOLOGY 1996;3:714-717.
27. Naoumov NV, Smith C, Williams R. Emergence and characterization of lamivudine resistant hepatitis B virus variant. HEPATOLOGY 1996;24:282.
28. Schalm SW. Clinical implications of lamivudine resistance by HBV Lancet 1997;9044:3-4.
29. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance immunocompetent chronic hepatitis B. J Hepatol 1997;26,1393-1395.
30. Lai CL, Liaw YF, Leung NWY, Deslauriers M, Barnard J, Sanathanan L, Gray DF, et al. Genotypic resistance to lamivudine in a prospective, placebo-controlled multicentre study in Asia of lamivudine therapy for chronic hepatitis B infection: incidence, kinetics of emergence, and correlation with disease parameters [Abstract]. HEPATOLOGY 1997;26:259A.
31. Ono Y, Onda H, Sasada R, Igarashi K, Sugino Y, Nishioka K. The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw. Nucleic Acids Res 1983;11,1747-1757.
32. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989;339: 237-238.
33. Back NT, Nijhhuis M, Kulen W, Boucher CA, Essink BB, Kuilenburg AB, Gennip AH, Berkhout B. Reduced replication of 3TC-resistant HIV-1 Variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBOJ 1996;15,4040-4049